Additional file 1 of Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens

Additional file 1: Table S1. ICI outcomes assigned to each study sample. Table S2. Detailed lung cancer cohort patient description. Table S3. Classifying FSPs in full cohort all-response model. Table S4. Classifying FSPs in response model without stable disease. Table S5. Classifying FSPs in monotherapy response model. Table S6. Classifying FSPs in NSCLC response model. Table S7. Classifying FSPs in adverse event model. Table S8. GO analysis of source genes for the classifying FSPs comprising the response without SD and monotherapy response models. Table S9. Expression levels* of source genes for irAE-classifying FSPs.

附加文件1：表S1。分配至各研究样本的免疫检查点抑制剂（Immune Checkpoint Inhibitor, ICI）治疗结局。表S2。肺癌队列患者详细资料。表S3。全队列全应答模型中的功能特征谱（Functional Signature Profiles, FSPs）分类结果。表S4。不含稳定疾病（Stable Disease, SD）的应答模型中的功能特征谱（FSPs）分类结果。表S5。单药治疗应答模型中的功能特征谱（FSPs）分类结果。表S6。非小细胞肺癌（Non-Small Cell Lung Cancer, NSCLC）应答模型中的功能特征谱（FSPs）分类结果。表S7。不良事件模型中的功能特征谱（FSPs）分类结果。表S8。针对构成无SD应答模型与单药治疗应答模型的分类用FSPs的源基因进行的基因本体（Gene Ontology, GO）分析。表S9。用于免疫相关不良事件（Immune-Related Adverse Event, irAE）分类的FSPs的源基因表达水平*